These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 33738859)
21. An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism. Asa SL; Ezzat S J Clin Med; 2021 May; 10(11):. PubMed ID: 34067494 [TBL] [Abstract][Full Text] [Related]
22. Production of alpha-subunit of glycoprotein hormones by pituitary somatotroph adenomas in vitro. Kontogeorgos G; Asa SL; Kovacs K; Smyth HS; Singer W Acta Endocrinol (Copenh); 1993 Dec; 129(6):565-72. PubMed ID: 7509101 [TBL] [Abstract][Full Text] [Related]
23. Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors. Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ Endocr Pathol; 2020 Jun; 31(2):150-155. PubMed ID: 32193825 [TBL] [Abstract][Full Text] [Related]
24. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version]. Xie J; Wu ZB Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420 [TBL] [Abstract][Full Text] [Related]
25. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours. Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902 [TBL] [Abstract][Full Text] [Related]
26. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Obari A; Sano T; Ohyama K; Kudo E; Qian ZR; Yoneda A; Rayhan N; Mustafizur Rahman M; Yamada S Endocr Pathol; 2008; 19(2):82-91. PubMed ID: 18629656 [TBL] [Abstract][Full Text] [Related]
27. Somatostatin receptor subtype gene expression in pituitary adenomas. Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115 [TBL] [Abstract][Full Text] [Related]
28. Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease. Rak B; Maksymowicz M; Pękul M; Zieliński G Front Endocrinol (Lausanne); 2021; 12():672178. PubMed ID: 34135861 [TBL] [Abstract][Full Text] [Related]
29. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Iacovazzo D; Carlsen E; Lugli F; Chiloiro S; Piacentini S; Bianchi A; Giampietro A; Mormando M; Clear AJ; Doglietto F; Anile C; Maira G; Lauriola L; Rindi G; Roncaroli F; Pontecorvi A; Korbonits M; De Marinis L Eur J Endocrinol; 2016 Feb; 174(2):241-50. PubMed ID: 26586796 [TBL] [Abstract][Full Text] [Related]
30. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Mete O; Kefeli M; Çalışkan S; Asa SL Mod Pathol; 2019 Apr; 32(4):484-489. PubMed ID: 30390035 [TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor expression and clinical outcome of multilineage pituitary tumours expressing PIT1 and SF1. Fookeerah P; Varikatt W; Shingde M; Dexter MAJ; McLean M Endocr Connect; 2023 Nov; 12(11):. PubMed ID: 37851558 [TBL] [Abstract][Full Text] [Related]
32. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Fougner SL; Casar-Borota O; Heck A; Berg JP; Bollerslev J Clin Endocrinol (Oxf); 2012 Jan; 76(1):96-102. PubMed ID: 21722151 [TBL] [Abstract][Full Text] [Related]
33. A clinicomorphological study of pituitary tumors associated with the clinical syndrome of acromegaly. Andreeva M; Georgiev T; Bosadjieva E; Karagiosov L; Karagiosov K; Tomova A; Matrosov P; Kirilov G; Diankov L; Christova T Exp Clin Endocrinol; 1991; 98(3):223-7. PubMed ID: 1778242 [TBL] [Abstract][Full Text] [Related]
34. Overview of the 2022 WHO Classification of Pituitary Tumors. Asa SL; Mete O; Perry A; Osamura RY Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028 [TBL] [Abstract][Full Text] [Related]
35. The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations. Dumitriu-Stan RI; Burcea IF; Nastase VN; Ceaușu RA; Dumitrascu A; Cocosila LC; Bastian A; Zurac S; Raica M; Poiana C Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003353 [TBL] [Abstract][Full Text] [Related]
37. Preoperative prediction of granulation pattern subtypes in GH-secreting pituitary adenomas. Heng L; Liu X; Jia D; Guo W; Zhang S; Gao G; Gong L; Qu Y Clin Endocrinol (Oxf); 2021 Jul; 95(1):134-142. PubMed ID: 33738801 [TBL] [Abstract][Full Text] [Related]
38. Primary Pituitary Carcinoids Do Not Exist: A Reappraisal in the Era of Pituitary Neuroendocrine Tumours. Armeni E; Alexandraki KI; Roncaroli F; Grossman AB Arch Med Res; 2023 Dec; 54(8):102841. PubMed ID: 37394342 [TBL] [Abstract][Full Text] [Related]